United States Renal Data System 2005 Annual Data Report Abstract

AJKD

VOL 47, NO 1, SUPPL 1, JANUARY 2006

American Journal of Kidney Diseases PREFACE

United States Renal Data System 2005 Annual Data Report Abstract Allan J. Collins, MD, Bertram Kasiske, MD, Charles Herzog, MD, Blanche Chavers, MD, Robert Foley, MB, David Gilbertson, PhD, Richard Grimm, MD, PhD, Jiannong Liu, PhD, Thomas Louis, PhD, Willard Manning, PhD, Arthur Matas, MD, Marshall McBean, MD, Anne Murray, MD, Wendy St. Peter, PharmD, Jay Xue, DVM, PhD, Qiao Fan, MS, Haifeng Guo, MS, Qi Li, MS, Shuling Li, MS, Suying Li, MS, Tricia Roberts, MS, Jon Snyder, MS, Craig Solid, MS, Changchun Wang, MS, Eric Weinhandl, MS, Cheryl Arko, BA, Shu-Cheng Chen, MS, Frederick Dalleska, MS, Frank Daniels, BS, Stephan Dunning, BA, James Ebben, BS, Eric Frazier, BS, Roger Johnson, Daniel Sheets, BS, Xinyue Wang, BA/BS, Beth Forrest, BBA, Delaney Berrini, BA, Edward Constantini, MA, Susan Everson, PhD, Pamela Frederick, MD, Paul Eggers, PhD, and Lawrence Agodoa, MD

T

HIS 17TH ANNUAL Data Report reports data through 2003. The US End-Stage Renal Disease Program entered 102,567 patients during 2003 and had 452,957 prevalent patients. Sixteen thousand transplantations were performed, and 128,131 patients had functioning grafts at year end. Incident rates have stabilized and decreased for most groups younger than 60 years. However, rates in younger black patients with diabetes show continued growth in contrast to decreased rates among whites. Care of the dialysis population continues to improve, with 91% of hemodialysis patients reaching treatment targets. Fistula use reached 37% in prevalent patients, with attempted placements doubling since 1996. Dialysis catheter placement rates have decreased, and hospitalization rates for vascular access infections have decreased for the first time in 10 years. Diabetes care is improving, but only 1 patient in 4 receives minimal glycemic control, lipid monitoring, and glucose test strips, and only 3.2% receive more comprehensive monitoring. The number of revascularization procedures continues to increase, and subsequent survival has improved, particularly in those receiving a stent. Care of patients with chronic

kidney disease has improved, but employer group health plans lag behind Medicare in most aspects of care. End-stage renal disease costs exceeded $27 billion in 2003, representing 6.7% of Medicare expenditures. Seven percent of Medicare patients have recognized kidney disease, yet they are associated with 24% of expenditures. Employers spend 7.3% of their budgets on patients with chronic kidney disease, exceeding costs for those with congestive heart failure (6.5%). The public health impact of kidney disease is larger than previously appreciated and needs greater attention to reduce its burden to patients, families, and the health care system. SUGGESTED CITATION

US Renal Data System: Excerpts from the USRDS 2005 Annual Data Report. Am J Kidney Dis 47:S1-S286 (suppl 1). Publications based upon USRDS data reported here or supplied upon request must include this citation and the following notice: © 2005 by the National Kidney Foundation, Inc. 0272-6386/05/4701-0101$30.00/0 doi:10.1053/j.ajkd.2005.12.001

American Journal of Kidney Diseases, Vol 47, No 1, Suppl 1 (January), 2006: pp v-vi

v

vi

The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US government.

PREFACE

ACKNOWLEDGMENT The staff at the USRDS Coordinating Center is again grateful to the publishers of the American Journal of Kidney Diseases for the opportunity to present the Annual Data Report. Funding for the USRDS Coordinating Center is provided under contract to the Minneapolis Medical Research Foundation (MMRF; contract #N01-DK-9-2343).